Corrigendum to “Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America” (Journal of Cardiac Failure (2019) 25(8) (584–619), (S1071916419305214), (10.1016/j.cardfail.2019.05.007))

In the above article a correction is needed. On page 601, left hand column, in the “Use of Glucose-Lowering Medications With CKD” section, first paragraph, the last sentence read, “Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min⁻¹·1.73 m⁻², ongoing trials (CANVAS [just stopped prematurely for efficacy]…” It should have read,” Although current recommendations are that SGLT-2 inhibitors should not be used with eGFR <30 mL·min⁻¹·1.73